Avalo Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Avalo Therapeutics (Nasdaq: AVTX) announced management will participate in four investor conferences in November–December 2025 with scheduled fireside chats:

• Guggenheim Healthcare Innovation Conference — Nov 10, 2025 at 4:00 pm ET
• Stifel 2025 Healthcare Conference — Nov 12, 2025 at 2:40 pm ET
• TD Cowen Immunology & Inflammation Summit — Nov 13, 2025 at 9:00 am ET
• Piper Sandler 37th Annual Healthcare Conference — Dec 2, 2025 at 10:30 am ET

Live webcasts and archived replays (available for at least 30 days when provided) will be posted under News / Events in the Investors section at https://ir.avalotx.com.

WAYNE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences:

Guggenheim Second Annual Healthcare Innovation Conference
Fireside Chat
November 10, 2025, at 4:00 pm ET

Stifel 2025 Healthcare Conference
Fireside Chat
November 12, 2025, at 2:40 pm ET

TD Cowen 1^st Immunology & Inflammation Summit
Fireside Chat
November 13, 2025, at 9:00 am ET

Piper Sandler 37^th Annual Healthcare Conference
Fireside Chat
December 2, 2025, at 10:30 am ET

Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead asset, AVTX-009, is in a Phase 2 clinical trial for hidradenitis suppurativa (HS). We’re also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. For more information about Avalo, please visit www.avalotx.com.

About AVTX-009 

AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a pro-inflammatory cytokine that plays a central role in the pathogenesis of a wide range of human diseases.¹ It activates immune cells that generate proinflammatory cytokines, including IL-6, TNF-α, and IL-17. Dysregulated IL-1β signaling is a major driver of inflammation, contributing to the progression of autoimmune disorders. IL-1β inhibition has proven effective in multiple immune-mediated inflammatory diseases.^1-3

References:¹Dinarello CA. Immunol Rev. 2018;281(1):8-27. ²Kany S et al. Int J Mol Sci. 2019;20(23):6008. ³Kimball AB et al. Presented at: American Academy of Dermatology; March 8-12, 2024; San Diego, CA.

For media and investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com 
410-803-6793

or

Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com 

FAQ

When will Avalo Therapeutics (AVTX) present at the Guggenheim Healthcare Innovation Conference?

Avalo will present a fireside chat on Nov 10, 2025 at 4:00 pm ET.

How can investors watch Avalo Therapeutics (AVTX) presentations from the Nov–Dec 2025 conferences?

Live webcasts and replays, when available, will be posted under News / Events on the company's investor site at https://ir.avalotx.com.

What date and time is Avalo's fireside chat at the Stifel 2025 Healthcare Conference?

The Stifel fireside chat is scheduled for Nov 12, 2025 at 2:40 pm ET.

Will Avalo Therapeutics (AVTX) webcast the TD Cowen Immunology & Inflammation Summit session?

The company said webcasts and replays will be provided when available via its investor site; the TD Cowen session is on Nov 13, 2025 at 9:00 am ET.

How long will replays of Avalo Therapeutics (AVTX) conference webcasts remain available?

Archived webcasts will be available for replay for at least 30 days when posted.